New research suggests that targeting a particular cell signalling pathway with the diabetes drug metformin might offer a way to stop the progression and spread of pancreatic cancer.
The study — which was led by Rutgers Cancer Institute of New Jersey in New Brunswick — is to feature at the 2018 annual meeting of the American Association for Cancer Research, which will be held in Chicago, IL.
This study is not the first to suggest metformin as a potential treatment for pancreatic cancer, but it is the first to show that the underlying mechanism involves the drug’s effect on the Rearranged during Transfection (RET) cell signalling pathway.
The estimates for the United States suggest that around 55,440 people will find out that they have pancreatic cancer in 2018, and approximately 44,330 people will die of the disease.
Though it is only responsible for 3 percent of all cancers in the U.S., pancreatic cancer accounts for around 7 percent of deaths from cancer.
Because pancreatic cancer is hard to detect in the early stages, most cases are not diagnosed until the disease has started to spread. This makes it harder to treat and often leaves people with much poorer prospects compared with other types of cancer. By Catharine Paddock PhD
GP Dr Michael Mosley was diagnosed with Type 2 diabetes four years ago and rather than start on medication – he invented the 5:2 diet – resulting in him losing weight and reversing his diabetes diagnosis. Dr Mosley will be telling us how you can do the same on a similar diet – watch this short video!
Elpis Ethos – Medical-Grade ECG Technology Monitoring & USB Charging
Introducing Elpis Ethos — a modern, sleek design with medical-grade, state-of-the-art ECG monitoring technology. Ethos is our top-seller for accurate, highly-advanced wellness monitoring.
The Ethos has a newer styled face, a comfortable hypo-allergenic band and USB charging. No need to ever worry about losing or breaking a charging cable for your wearable again. Ethos charges by using any USB port.
Ethos‘s main feature is the astounding recording of your own heart’s ECG rhythm. Recordings of the results can be sent to anyone you designate and can be printed.
Get 10% Off Any ELPIS Product!
Use The Following Coupon Code At Checkout:
Dexcom has announced that it plans to launch its new continuous glucose monitor (CGM), the G6, in late 2018.
Early data has shown the G6 to be the most accurate device the California-based tech company has released. One study involving 49 participants found the G6 collected 96 per cent of blood glucose readings within 20 mg/dl of the true glucose value.
The G6 will be one of the first products to emerge from Dexcom’s partnership with tech giant Verily (formerly Google Life Sciences).
It will feature a 10-day wear with just one fingerstick calibration per day. In comparison, Dexcom’s G4 and G5 devices both require twice-daily calibration.
Dexcom plans to submit the G6 for US Food and Drug Administration (FDA) approval later this year, with commercialisation the planned for the end of 2018.
Shown off at CES 2017 at the start of the year, K’Watch Glucose was among about two dozen products designated a winner of the show’s Best of Innovation Award. Utilizing a revolutionary biosensor, the device works by “tasting” the skin rather than taking blood samples.
Their proprietary system is composed of biosensors that use micro-needles to probe interstitial fluid for bio-chemical analysis. While the user will feel the slight pressure of the probe pressing on their skin, they feel absolutely no pain as the sensor never reaches any nerve or blood vessel.
The technology is housed in something the company calls K’apsul. One of these is good for a month before it needs to be changed, and you can take unlimited measurements during this period. Its worth noting, glucose is not recorded automatically or continuously. A user needs to press K’Watch on the skin for a measurement to be taken.
Results are displayed on the K’Watch Glucose screen as well as synced to the accompanying app. The device can also send alerts to remind users to check their glucose level. And you get some standard fitness tracking functions as well such as steps taken, distance traveled and calories burnt.
“K’Track Glucose is the first accurate non-blood-based glucose monitor to be built directly into a wearable device,” said PKvitality in a press release.
“It combines the elegance and utility of traditional activity trackers with the life-changing information of a medical device.”
In addition to the watch, the technology also comes in the form of an armband. Dubbed K’Watch Athlete, this is a more expensive version that allows athletes to monitor the lactic acid level in real time. K’Watch Athlete also allows for continuous measurement of glucose. Users just need to decide the recording interval between each measurement.
K’Track Glucose starts at $150, K’Track Athlete at $200 and each removable K’apsul will set you back $100. Unfortunately, this is not something that you will be able to pick up in the store in a few weeks time.
If all goes well, first deliveries will start by the end of 2018, once the medical certification process is out of the way.